The reproducible panel of 10 TAAs, included novel HCC antigens such as Gankyrin and CK8, achieved the specificity of 91% and sensitivity of 41%, even upon partial scale-up of antigen and despite the fact that 3 of the originally identified antigens were no longer found to be additive to the panel, illustrating that optimisation of protein production prior to commercial launch of a test, is paramount. Here, KRT8 is linked to hepatocellular carcinoma.